The Reemergence of Ketamine for Treatment in Critically Ill Adults Kimberly P. Hurth, Kristen B. Thomas, Michael A. Rudoni Critical Care Medicine, 2020,1-13. Doi : 10.1097/CCM.0000000000004335 Objectives : To assess the evidence and discuss the risks and clinical relevance of ketamine for the treatment of various disease states impacting the adult critically ill population. Data Sources : A literature review was performed using PubMed evaluating primary literature published until August 2018. Study Selection : Case reports, observational studies (cohort, case-control), and randomized controlled trials involving patients 18 years and older in a nonperioperative setting using either IV or intramuscular ketamine were included for analysis. Uses of [...]
Lire la suiteBIBLIOGRAPHIE : Substances psychédéliques : Généralités, Épistémologie, Pharmacologie, Neurophysiologie, Psychologie, … Dr Christian SUEUR, GRECC, mai 2020 (nouvelle version) Substances psychédéliques : Généralités, Pharmacologie, Neurophysiologie : 1 - 17 Substances psychédéliques et «psychologie » : 18 - 20 Cf également : Bibliographie : Thérapies psychédéliques, Bibliographie : Substances psychédéliques, culture, chamanisme, spiritualité, religion… Bibliographie : Psilocybine, Bibliographie : LSD, Bibliographie : Ayahuasca, Bibliographie : Mescaline et Peyotl, Bibliographie : MDMA, Bibliographie : Tryptamines …
Lire la suiteBibliographie : Cannabis et Cannabinoides en Psychiatrie, Docteur Christian Sueur, GRECC, avril 2020
Bibliographie : Cannabis et Cannabinoides en Psychiatrie Docteur Christian Sueur, GRECC, avril 2020. 1 - Généralités : 1 - 11 2 - Cannabidiol anxiolytique : 12 - 14 3 - Cannabidiol antipsychotique : 15 - 20 4 - Cannabinoïdes et dépression : 21 - 24 5 - Cannabidiol antidépresseur : 25 6 - Cannabinoïdes et Sommeil : 26 - 27 7 - Cannabinoïdes et addiction au Cannabis : 28 - 337 8 - Cannabinoïdes et addictions (cocaine, opiacés, amphétamines, alcool, tabac) : 38 - 52 9 - Cannabinoides et syndrome de Gilles de la Tourette : 53 - 54 10 - Cannabinoides et Hyperactivité - Déficit de l’Attention (HA-DA, TDAH) : 55 - 56 11 - Cannabinoides et PTSD : 57 - 60 12 [...]
Lire la suiteCANNABIDIOL (CBD), Pre-Review Report, Agenda Item 5.2 Expert Committee on Drug Dependence Thirty-ninth Meeting, Geneva, 6-10 November 2017 39th ECDD (2017) Agenda item 5.2 Cannabidiol (CBD) Contents Acknowledgements .................................................................................................................. 4 Summary ................................................................................................................................... 5 1. Substance identification ........................................................................................................ 6 A. International Nonproprietary Name (INN) .......................................................................... 6 B. Chemical Abstract Service (CAS) Registry Number .............................................................. 6 C. Other Chemical Names .......................................................................................................... 6 D. Trade Names .......................................................................................................................... 6 E. Street Names .......................................................................................................................... 6 F. Physical Appearance .............................................................................................................. 6 G. WHO Review History ............................................................................................................. 6 2. Chemistry ............................................................................................................................... 6 A. Chemical Name ...................................................................................................................... 6 B. Chemical Structure ................................................................................................................. 7 C. Stereoisomers ......................................................................................................................... 7 D. Methods and Ease of Illicit Manufacturing ............................................................................ 7 E. Chemical Properties ............................................................................................................... 9 F. Identification and Analysis ..................................................................................................... 9 3. Ease of [...]
Lire la suiteBibliographie MDMA - Ecstasy Docteur Christian Sueur, GRECC, mars 2020 MDMA : généralités, sociologie…, p 1. MDMA : pharmacologie, p 2. MDMA : neurophysiologie, p 6. MDMA : toxicologie, p 10. MDMA : analyses pharmacologiques, « réduction des risques », p 13. MDMA : psychopathologie, p 14. MDMA : enthéogénie, p 15. MDMA : thérapeutique, p 16.
Lire la suiteIs there a role for cannabidiol in psychiatry ? Julia Machado Khoury , Maila de Castro Lourenço das Neves, Marco Antônio Valente Roque, Daniela Alves de Brito Queiroz , Andre Augusto Corrêa de Freitas, Angelo de Fatima, Fabrıcio Moreira and Frederico Duarte Garcia The World Journal of Biological Psychiatry, 2017, 16 p. Doi : 10.1080/15622975.2017.1285049 ABSTRACT Objectives : Understanding whether cannabidiol (CBD) is useful and safe for the treatment of psychiatric disorders is essential to empower psychiatrists and patients to take good clinical decisions. Our aim was to conduct a systematic review regarding the benefits and adverse events (AEs) of CBD in the treatment of schizophrenia, psychotic [...]
Lire la suiteClinical and Toxicological Profile of NBOMes : A Systematic Review Nino Cesar Marchi, Juliana Nichterwitz Scherer, Letícia Schwanck Fara, Lysa Remy, Rafaela Ornel, Monique Reis, Amanda Zamboni, Mariana Paim, Taís Regina Fiorentin, Carlos Alberto Yasin Wayhs, Lisia Von Diemen, Flavio Pechansky, Felix Henrique Paim Kessler, Renata Pereira Limberger Psychosomatics, 2019 Mar - Apr, 60, (2), 129-138. doi : 10.1016/j.psym.2018.11.002 Background : NBOMes are a new class of potent hallucinogens widely present in illicit drugs. Little is known about this class of drugs, regarding its detection and clinical manifestations of intoxication. Objective : This study aims to enhance care involving NBOMes by reviewing the literature on their [...]
Lire la suiteA novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol : Δ9-Tetrahydrocannabiphorol Cinzia Citti, Pasquale Linciano, Fabiana Russo, Livio Luongo, Monica Iannotta, Sabatino Maione, Aldo Laganà, Anna Laura Capriotti, Flavio Forni, Maria Angela Vandelli, Giuseppe Gigli & Giuseppe Cannazza Scientific Reports | (2019) 9:20335 | www.nature.com/scientificreports Doi : 10.1038/s41598-019-56785-1 (-)-Trans-Δ9-tetrahydrocannabinol (Δ9-THC) is the main compound responsible for the intoxicant activity of Cannabis sativa L. The length of the side alkyl chain influences the biological activity of this cannabinoid. In particular, synthetic analogues of Δ9-THC with a longer side chain have shown cannabimimetic properties far higher than Δ9-THC [...]
Lire la suiteTHCp – Newly discovered and highly potent phytocannabinoid Source : cannabislifenetwork.com Publié le 1 Fév 2020 We have discovered so much about cannabis over the years, but it’s vast, intricate, pharmacological map is missing many major regions. CBD dominant varieties have exploded in demand, yet the cannabinoid is still only partially understood, and there is still CBG and CBN just around the market’s corner. Now, brand new forms of THC and CBD, THCp and CBDp, respectively, have been discovered; evidence that the map’s expanse is still beyond our grasp. Phytocannabinoids over synthetics Lately, stories of newly discovered cannabinoids are strewn with the accomplishments of a biochemist [...]
Lire la suiteMedicinal cannabis for psychiatric disorders: a clinically-focused systematic review Jerome Sarris, Justin Sinclair, Diana Karamacoska, Maggie Davidson and Joseph Firth BMC Psychiatry, 2020, 20, 24, 1-14. Doi : 10.1186/s12888-019-2409-8 Abstract Background : Medicinal cannabis has received increased research attention over recent years due to loosening global regulatory changes. Medicinal cannabis has been reported to have potential efficacy in reducing pain, muscle spasticity, chemotherapy-induced nausea and vomiting, and intractable childhood epilepsy. Yet its potential application in the field of psychiatry is lesser known. Methods : The first clinically-focused systematic review on the emerging medical application of cannabis across all major psychiatric disorders was conducted. Current evidence regarding [...]
Lire la suite